Abstract: A method for disrupting a sample of biological material of human, animal, or plant origin for subsequent proteome analysis by a mass spectrometry method is provided. The method involves disrupting the sample by treatment with a certain volume of an organic acid until the sample completely dissolves, incubating the sample for a certain period, and then neutralizing the sample with a neutralizing solution until a pH value between 7 and 9 is reached.
Type:
Grant
Filed:
December 27, 2018
Date of Patent:
November 2, 2021
Assignee:
FEDERAL REPUBLIC OF GERMANY LAST REPRESENTED BY THE ROBERT-KOCH-INSTITUT WHICH IS REPRESENTED BY ITS PRESIDENT
Inventors:
Andy Schneider, Jörg Döllinger, Peter Lasch
Abstract: The present invention relates to a delivery system suitable for delivering a substance into a XCR1 positive professional antigen-presenting cell, one or more nucleic acids coding for the same, a vector comprising the nucleic acid(s), a medicament comprising the delivery system or the one or more nucleic acid(s) and an adjuvant comprising XCL1 or a functionally active fragment thereof.
Type:
Grant
Filed:
November 19, 2008
Date of Patent:
July 7, 2020
Assignee:
BUNDESREPUBLIK DEUTSCHLAND LETZVERTRETEN DURCH DAS ROBERT KOCH-INSTITUT VERTRETEN DURCH SEINEN PRAESIDENTEN
Abstract: The present invention relates to a medicament for use in a method of extending a cellular cytotoxic immune response against an antigen-comprising protein, the method comprising the step of: i) administering to a patient having T cells activated against an antigen a peptide-loaded major histocompatibility complex class I (MHC-I) presenting cell and an adjuvant which supports a Th-1-mediated response, wherein the peptide is derived from the antigen-comprising protein, thereby re-activating the activated T cell, wherein the peptide-loaded major histocompatibility complex class I (MHC-I) presenting cell of step i) is administered in a time frame of from 0 h to 14 days after the T cells were activated against an antigen.
Type:
Grant
Filed:
March 17, 2015
Date of Patent:
June 23, 2020
Assignee:
Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten
Abstract: The present invention relates generally to binding agents useful in the selective depletion of T cells in vivo. More specifically, the invention relates to ICOS-binding agents which once bound to ICOS expressed on the surface of cells, in particular ICOS-bearing activated T cells, result in the in vivo depletion of cells to which they are bound. Methods of treating T cell related diseases using said ICOS-binding agents, and pharmaceutical compositions comprising said ICOS-binding agents, a method of identifying an ICOS-binding agent, and monoclonal anti-ICOS antibodies capable of eliminating cells in vivo which express ICOS on their surface are also provided.
Type:
Grant
Filed:
October 22, 2012
Date of Patent:
December 23, 2014
Assignee:
Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten
Abstract: The present invention relates to a delivery system suitable for delivering a substance into a XCR1 positive professional antigen-presenting cell, one or more nucleic acids coding for the same, a vector comprising the nucleic acid(s), a medicament comprising the delivery system or the one or more nucleic acid(s) and an adjuvant comprising XCL1 or a functionally active fragment thereof.
Type:
Application
Filed:
November 19, 2008
Publication date:
December 9, 2010
Applicant:
Bundesrepublik Deutschland letztvertreten durch das Robert Koch-Institut vertreten durch seinen
Abstract: The present invention relates to a method for specifically detecting Ljungan virus (LV). In particular, the present invention relates to a method of detecting LV using quantitative real-time reverse transcriptase PCR. The present invention also provides kits for performing the method of the invention.
Type:
Grant
Filed:
March 15, 2006
Date of Patent:
September 28, 2010
Assignees:
Apodemus AB, Robert-Koch Institut
Inventors:
Bo Niklasson, Andreas Nitsche, Oliver Donoso Mantke, Matthias Niedrig
Abstract: A method for diagnosing TSE-induced pathologic changes in tissues including the steps of: (a) directing infrared radiation to a tissue sample with pathologic changes caused by TSE, recording its spectral characteristics after irradiation and (b) comparing and classifying the infrared spectra thus obtained with a reference database containing infrared spectra of TSE-infected tissues and non-infected tissues.
Type:
Grant
Filed:
March 6, 2002
Date of Patent:
August 17, 2004
Assignee:
Robert-Koch-Institut
Inventors:
Dieter Naumann, Janina Kneipp, Elizabeth Baldauf, Peter Lasch, Michael Beekes